Interview with Dr James Garner, CEO of Kazia Therapeutics
Regulatory May 25, 2023Report from Annual General Meeting in Vivesto AB
Regulatory May 25, 2023Interim report for the period January 2023 – March 2023
Regulatory April 25, 2023Notice of Annual General Meeting in Vivesto AB
Vivesto published its Q1 report for 2023 on May 25, 2023, at 08.00 am CEST.
Oasmia acquires global development and commercialization rights for Cantrixil, a clinical stage, ovarian cancer program